Type II refractory celiac disease has been added to the list of entities in the ICC, as this represents an “in situ” neoplastic condition precursor to EATL, and recent works have shown that it often already harbors driving mutations in JAK1 and/or STAT3 similar to those present in EATL [6]. Here, JAK1 is linked to enteropathy-associated T-cell lymphoma.